Across TCGA pan-cancer cohorts, TRIM16 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRIM16 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRIM16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM16 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and LSCC are the cancer types where TRIM16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.367	0.861	.018	12	view →
UCEC	DFS	Quartile	All	0.886	0.216	.020	10	view →
LSCC	DFS	Quartile	All	0.868	1.000	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRIM16 tumor-vs-normal RNA expression · all TRIM16 data types